Table 4 Main characteristics of studies used for discussion purposes
From: Minimising radiation exposure in catheter ablation of ventricular arrhythmias
Author, year | ZF/MinF/F | Number of patients | Type of study | Type of VA | Procedural duration | OSR | RR | CR | Epicardial ablation, % of procedures | Use of fluoroscopy | Fluoroscopy time and dose | Use of ICE, % of procedures |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Our study, 2021 | MinF | 52 | Retrospective, consecutive pts | PVC, Idiopathic VT and SHD related VT (NICM, ICM) | 123.6 ± 42.2 min for PVC and idiopathic VT, 256.9 ± 71.7 min for SHD related VT | 89.7% for PVC and idiopathic VT, 77.4% for SHD related VT | 29.6% for PVC and idiopathic VT, 32% for SHD related VT | 5% | Yes, in 10% for SHD related VT | Yes, 14% for PVC and idiopathic VT, 10% for SHD related VT | 8.3 ± 4 min and 25.4 ± 14 Gycm2 when used for PVC and idiopathic VT; 21.2 ± 5 min and 48.6 ± 32 Gycm2 when used in SHD related VT | Yes, 100% |
Dinov et al., 2014 | F | 227 | Prospective | SHD related VT (NICM, ICM) | 181 ± 63.6 min for NICM and 155 ± 49 min for ICM | 66.7% for NICM and 77.4% ICM | 59.5% for NICM and 43% for ICM | 11.1% for NICM and ICM | Yes, 9% | Yes, 100% of procedures | 39 ± 22.4 min for NICM and 26 ± 19.1 min for ICM, dose not reported | No |
Tanawuttivat et al., 2015 | F | 815 in 8 different studies | Review with analysis | Idiopathic/outflow tract VT | Not reported in the review | 76–100% | 0–23% | 0–3% | No | Yes | Not reported in the review | No |
Kumar et al., 2016 | F | 695 | Retrospective, consecutive pts | Idiopathic VT and SHD related VT (NICM, ICM) | Not reported | 79% for idiopathic VT, 60% for NICM and 56% for ICM | At 6 years FU: 23% for idiopathic VT, 62% for NICM and 46% for ICM | 3.7% for idiopathic VT, 6.7% for NICM, 8.3% for ICM | Yes, 3% for idiopathic VT, 30% for NICM and 8% for ICM | Yes | 31.3 ± 20 min for idiopathic VT, 43 ± 21.6 for NICM and 45.1 ± 30.2 for ICM, dose not reported | No |
Lamberti et al., 2015 | ZF | 19 | Retrospective, consecutive pts | PVC, idiopathic VT | 170.2 ± 45.7 min | 100% | 10.5% | 0 | No | No | 0 | Yes, 100% |
Sanchez et al., 2016 | ZF | 16 | Retrospective, consecutive pts | PVC, Idiopathic VT and SHD related VT (aetiology not specified) | 150 ± 45 min | 100% | Not reported | 0 | No | No | 0 | Yes, 75% |
Razminia et al., 2017 | ZF | 44 | Retrospective, consecutive pts | PVC, Idiopathic VT and SHD related VT (ICM) | 201.9 min for PVC, 257.5 min for idiopathic VT and SHD related VT | 93.3% for PVC, 100% for idiopathic VT and SHD related VT | 6.6 for PVC, 21.4 for idiopathic VT and SHD related VT | 3.3% for PVC, 0 for idiopathic VT and SHD related VT | No | No | 0 | Yes, % not specified |
Giaccardi et al., 2019 | ZF | 7 | Retrospective | PVC, VT (aetiology not specified) | 75 min for PVC, 128 ± 21 min for VT | 100% | 0 | 0 | No | No | 0 | No |
Sadek et al., 2019 | ZF | 10 | Prospective | PVC, SHD related VT (aetiology not specified) | Not reported | 100% | 0 for PVC, 17% for SHD related VT | 0 | No | No | 0 | Yes, 100% |
Cano et al., 2016 | MinF | 41 | Prospective | SHD related VT (NICM, ICM) | 204 ± 61 min | 66% | 7.3% | 4.9% | Yes, 16% | Yes | 6.08 (1.51–12.36) min and 10.8 (2.9–41.1) Gycm2 | No |
Wang et al., 2017 | MinF | 160 | Prospective, multi-centre | PVC, idiopathic VT | 77.1 ± 33.8 min | 84.1% | 1.9% | 1.2% | No | Yes, 5.6% of procedures | 1.5 ± 0.3 min when used, dose not reported | No |